Trial Profile
An Open Label Phase 1 Study of Safety and Immunogenicity of JNJ-64041757, A Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects With Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemlimogene-merolisbac (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Janssen Research & Development
- 04 Jun 2019 Results evaluating immunogenicity, safety, and efficacy of JNJ-757 in patients with advanced NSCLC (adenocarcinoma) as monotherapy (phase 1) and in combination with nivolumab (phase 1b/2) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 21 Nov 2018 Status changed from active, no longer recruiting to discontinued.
- 13 Sep 2018 Status changed from recruiting to active, no longer recruiting.